Insmed - positive results from phase 2 willow study of brensocatib

Positive results from phase 2 willow study of brensocatib in patients with non-cystic fibrosis bronchiectasis presented at ats virtual clinical trials session.insmed inc - brensocatib shown to reduce time to first pulmonary exacerbation and reduce rate of exacerbations versus placebo.insmed inc - new data demonstrate relationship between neutrophil elastase reduction and risk of exacerbation in patients treated with brensocatib.insmed - willow study met its primary endpoint.insmed inc - brensocatib was generally well-tolerated in study.insmed - treatment with brensocatib 10 mg resulted in significant reduction in rate of pulmonary exacerbations versus placebo.insmed - plans to initiate phase 3 program for brensocatib in bronchiectasis in h2 2020.
INSM Ratings Summary
INSM Quant Ranking